Welcome to our dedicated page for Cybin news (Ticker: HELP), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cybin's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cybin's position in the market.
Helus Pharma (Nasdaq: HELP) welcomed a White House Executive Order on April 20, 2026, designed to accelerate research, regulatory review, and patient access for psychedelic therapies.
The company noted its lead candidate, HLP003, is in Phase 3 and has FDA Breakthrough Therapy designation for adjunctive major depressive disorder; Helus said it will continue late-stage development and regulatory engagement.
Helus Pharma (Nasdaq: HELP) announced a management change on April 20, 2026: CEO Michael Cola stepped down effective immediately and Co-founder and Executive Chairman Eric So will resume as Interim CEO while the Board conducts a search for a permanent successor.
The company said priorities remain advancing the clinical pipeline, including the APPROACH trial topline readout for HLP003 expected in the fourth quarter, and ensuring continuity of leadership during the transition.
Helus Pharma (Nasdaq: HELP) appointed Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs effective April 16, 2026. Dr. Kramer brings 25 years of neuroscience medical affairs experience, prior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie, and leadership on a recent schizophrenia product launch.
This hire aims to scale medical capabilities, deepen clinician and payor engagement, and support advancement of Helus's serotonergic agonist pipeline.
Helus Pharma (Nasdaq: HELP) announced the appointment of Jill Conwell as Chief People Officer, effective March 12, 2026.
Conwell brings more than two decades of life‑science leadership, including roles at Aclaris, Idera, and Shire, and will support talent, organizational scaling, and culture as Helus advances its clinical serotonergic agonist pipeline.
Helus Pharma (Nasdaq: HELP) reported topline Phase 2 signal detection results for HLP004 in adults with moderate-to-severe generalized anxiety disorder on standard-of-care therapy. Patients given 20 mg showed a mean 10.4-point HAM-A reduction at six weeks (p<0.0001), with 67% responders and 39% remitters at six months. The randomized 36-patient study (2:1 active:placebo) found acute effects lasting ~90 minutes and discharge readiness within ~3 hours, and noted no drug-related serious adverse events.
Helus Pharma (Nasdaq: HELP) appointed Dr. Freda Lewis-Hall to its Board of Directors and named her Chair of the Scientific Advisory Committee, effective Feb 24, 2026. Dr. Lewis-Hall brings 40+ years in psychiatry and industry leadership, including over a decade as Pfizer chief medical officer and global regulatory experience.
She will guide clinical development, regulatory engagement, and scientific governance across Helus’ novel serotonergic agonist portfolio; appointment is subject to Cboe Canada approval.
Helus Pharma (Nasdaq: HELP) reported a randomized, placebo-controlled Phase 2a trial of SPL026 in major depressive disorder that met its primary endpoint at two weeks (MADRS mean difference: -7.35; p=0.023).
Single 21.5 mg dose showed antidepressant effects within one week (mean difference: -10.75; p=0.002), durability to three months for the cohort, and no treatment-related serious adverse events reported.
Helus Pharma (Nasdaq: HELP) reported Q3 fiscal 2026 results and clinical progress on Feb 13, 2026. Cash totaled US$195.1 million as of Dec 31, 2025. Net loss was US$42.7 million for the quarter; cash-based operating expenses were US$36.7 million.
Pipeline updates: topline Phase 2 data for HLP004 in GAD expected Q1 2026; Phase 3 program for HLP003 in MDD continues with topline anticipated Q4 2026. IP protection extends around lead programs through at least 2041.
Helus Pharma (Nasdaq: HELP) named Michael Cola as Chief Executive Officer effective Feb 10, 2026, to lead late-stage development, commercialization, and capital formation.
The company highlighted expected clinical milestones: Phase 2 HLP004 data due this quarter and Phase 3 HLP003 topline in Q4 2026, plus >350 patent applications and >100 patents granted.
Helus Pharma (Nasdaq: HELP) announced its U.S. listing migration to the Nasdaq Global Market and ongoing trading on Cboe Canada under HELP, and said it will operate under the business name Helus Pharma. The company highlighted two lead programs: HLP003, a Phase 3 NSA with Breakthrough Therapy Designation for adjunctive major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder with a topline readout expected in Q1 2026. The company cited >350 filed patents (100+ granted) and said commercialization preparations for HLP003 are underway, subject to receipt of necessary approvals.